Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease

Silva, Inês; Solas, J; Pinto, Rui; Mateus, Vanessa

doi:10.3390/ijms23094739

Cited by 15 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They induce naïve T lymphocytes to become Tregs (as shown in Figure 6 ). Our results match those obtained in the same model by Silva et al 2022 [ 61 ], and IL-10 therapy ameliorates TNBS colitis [ 62 ]. Moreover, Vegfa was also correlated positively to Il10 and Tgfb1 networks and negatively to SAA, the latter in the therapeutic approach.…”

Section: Discussionsupporting

confidence: 92%

Response Variability to Drug Testing in Two Models of Chemically Induced Colitis

Suau

Garcia

Bernal

et al. 2023

IJMS

View full text Add to dashboard Cite

The lack of knowledge regarding the pathogenesis of IBD is a challenge for the development of more effective and safer therapies. Although in vivo preclinical approaches are critical for drug testing, none of the existing models accurately reproduce human IBD. Factors that influence the intra-individual response to drugs have barely been described. With this in mind, our aim was to compare the anti-inflammatory efficacy of a new molecule (MTADV) to that of corticosteroids in TNBS and DSS-induced colitis mice of both sexes in order to clarify further the response mechanism involved and the variability between sexes. The drugs were administered preventively and therapeutically, and real-time bioluminescence was performed for the in vivo time-course colitis monitoring. Morphometric data were also collected, and colonic cytokines and acute plasma phase proteins were analyzed by qRT-PCR and ELISA, respectively—bioluminescence images correlated with inflammatory markers. In the TNBS model, dexamethasone worked better in females, while MTADV improved inflammation in males. In DSS-colitis, both therapies worked similarly. Based on the molecular profiles, interaction networks were constructed to pinpoint the drivers of therapeutic response that were highly dependent on the sex. In conclusion, our results suggest the importance of considering sex in IBD preclinical drug screening.

show abstract

Section: Discussionsupporting

confidence: 92%

Response Variability to Drug Testing in Two Models of Chemically Induced Colitis

Suau

Garcia

Bernal

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Thereafter, 100 µL of 1% TNBS in 50% ethanol was administered through a catheter, carefully inserted until 4 cm into the colon. Then, mice were kept for 1 min in a Trendelenburg position to avoid reflux [ 18 , 29 ]. This procedure was performed on days 0, 7, 14, 21, and 28 of the experiment, over 5 weeks.…”

Section: Methodsmentioning

confidence: 99%

Anti-Inflammatory Effect of Topiramate in a Chronic Model of TNBS-Induced Colitis

Silva

Mendes

Guerra

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is characterized by a chronic and relapsing inflammatory response in the gastrointestinal tract, resulting in severe symptoms such as abdominal pain, vomiting, diarrhea, bloody stools, and weight loss. Currently, there is no cure, and the pharmacological treatment includes drugs that induce and keep the patient in remission, not reversing the underlying pathogenic mechanism. These therapies, in the long term, may cause various side effects and complications, which has increased the need to investigate new, more effective, and safer pharmacological approaches. In preclinical studies, topiramate has demonstrated a potential anti-inflammatory effect by inhibiting the production of several pro-inflammatory cytokines. This study aimed to investigate the effect of topiramate in a chronic TNBS-induced colitis model in rodents. Experimental colitis was induced by four intrarectal administrations of 1% TNBS in female CD-1 mice. Topiramate 10 and 20 mg were administered intraperitoneally for 14 days. Several parameters were evaluated, such as bodyweight, alkaline phosphatase (ALP), fecal hemoglobin, fecal calprotectin, tumor necrosis factor (TNF)-α, and interleukin (IL)-10. Topiramate reduces TNBS-induced colonic damage in a model of chronic experimental colitis and normalizes the stool consistency and anus appearance. Additionally, topiramate significantly reduced the concentration of ALP, fecal hemoglobin, fecal calprotectin, TNF-α, and IL-10, demonstrating it to be a promising pharmacological approach for the treatment of IBD in the future.

show abstract

“…The most commonly used method to induce inflammation using TNBS in ethanol solution is a one‐time enema. In addition, repeated administration of TNBS can also induce chronic colitis, such as introducing 100 μL of 1% TNBS in 50% ethanol near the anus through a polypropylene catheter five times within 4 weeks, which leads to colon mucosal structure damage, intestinal wall thickening, and inflammatory cell infiltration similar to the symptoms of chronic CD (Silva, Solas, Pinto, & Mateus, 2022). It is noteworthy that chronic colitis induced by TNBS exhibits a persistent property of lamina propria fibrosis, which can be employed to investigate the pathological mechanism underlying the intestinal fibrosis accompanying human IBD (Wirtz et al., 2017).…”

Section: Chemically Induced Ibd Modelsmentioning

confidence: 99%

An evaluation of animal models for using bioactive compounds in the treatment of inflammatory bowel disease

Tie,

Chen,

Tan

2024

Food Frontiers

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a prevalent chronic relapsing‐remitting disease that affects the digestive tract and reduces patients’ quality of life. Food bioactive compounds are a promising approach for nutritional intervention of IBD with minimal side effects. To evaluate their potential, researchers have developed various animal models that simulate human IBD, including chemically induced, spontaneous, genetically engineered, and adoptive transfer models. In this work, the main animal models, pathogenesis, symptoms, strengths, and limitations of IBD were discussed. Although these models could not perfectly replicate human IBD, they provided useful tools to study the disease's progression and therapeutic processes. In addition, taking these IBD animals as models, the specific experimental methods, intervention results, and mechanisms of food bioactive compounds to prevent or treat IBD were described in detail. The continuous improvement of animal models is crucial to gain a better understanding of IBD's etiology and pathogenesis and to evaluate the efficacy of food bioactive compounds for the effective control of IBD.

show abstract

Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease

Cited by 15 publications

References 47 publications

Response Variability to Drug Testing in Two Models of Chemically Induced Colitis

Response Variability to Drug Testing in Two Models of Chemically Induced Colitis

Anti-Inflammatory Effect of Topiramate in a Chronic Model of TNBS-Induced Colitis

An evaluation of animal models for using bioactive compounds in the treatment of inflammatory bowel disease

Contact Info

Product

Resources

About